Coherus Biosciences Inc (CHRS) concluded trading on Thursday at a closing price of $1.50, with 3.83 million shares of worth about $5.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.73% during that period and on December 12, 2024 the price saw a loss of about -9.09%. Currently the company’s common shares owned by public are about 115.21M shares, out of which, 110.58M shares are available for trading.
Stock saw a price change of -0.66% in past 5 days and over the past one month there was a price change of 82.15%. Year-to-date (YTD), CHRS shares are showing a performance of -54.95% which decreased to -28.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.66 but also hit the highest price of $3.70 during that period. The average intraday trading volume for Coherus Biosciences Inc shares is 5.23 million. The stock is currently trading 16.10% above its 20-day simple moving average (SMA20), while that difference is up 45.90% for SMA50 and it goes to -5.22% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Coherus Biosciences Inc (NASDAQ: CHRS) currently have 115.21M outstanding shares and institutions hold larger chunk of about 66.08% of that.
The stock has a current market capitalization of $172.82M and its 3Y-monthly beta is at 0.85. It has posted earnings per share of -$0.10 in the same period. It has Quick Ratio of 1.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CHRS, volatility over the week remained 11.82% while standing at 15.60% over the month.
Stock’s fiscal year EPS is expected to rise by 113.96% while it is estimated to decrease by -222.35% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on August 16, 2024 offering a Neutral rating for the stock and assigned a target price range of between $4 and $1.50 to it. Coverage by Robert W. Baird stated Coherus Biosciences Inc (CHRS) stock as an Outperform in their note to investors on November 17, 2023, suggesting a price target of $11 for the stock. On November 08, 2023, Maxim Group Downgrade their recommendations, while on July 24, 2023, Citigroup Initiated their ratings for the stock with a price target of $12. Stock get a Buy rating from Truist on May 01, 2023.
